Fig. 2: Determination of LoD of SHERLOCK assay for SARS-CoV-2 with different RPA-primer–crRNA combinations.
From: Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA
a, SARS-CoV-2 genome map showing four regions—one in S, one in N and two in Orf1ab genes—selected for SHERLOCK detection. Selected regions are annotated with coloured rectangles and their nucleotide positions. UTR, untranslated region. b, LoD of SHERLOCK assays for detection of different SARS-CoV-2 gene regions, using lateral-flow readout. All lateral-flow strips contain a test (T) and control (C) band. c,d, LoD of SHERLOCK assays for detection of different SARS-CoV-2 gene regions, using fluorescence readout. c, Kinetics of fluorescence signal generation over 60 min of CRISPR–Cas13a reaction for each detected gene at different RNA serial dilutions. RFU, relative fluorescence units. d, Quantification of fluorescence signals generated after 20 min of CRISPR–Cas13a reaction at each dilution. Data are mean ± s.d. from triplicate measurements. Negative controls have RNase-free water as input instead of RNA dilutions.
